AU2002215488B8 - Universal collection medium - Google Patents
Universal collection medium Download PDFInfo
- Publication number
- AU2002215488B8 AU2002215488B8 AU2002215488A AU2002215488A AU2002215488B8 AU 2002215488 B8 AU2002215488 B8 AU 2002215488B8 AU 2002215488 A AU2002215488 A AU 2002215488A AU 2002215488 A AU2002215488 A AU 2002215488A AU 2002215488 B8 AU2002215488 B8 AU 2002215488B8
- Authority
- AU
- Australia
- Prior art keywords
- medium
- cell
- analysis
- fixative
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims abstract description 55
- 238000007479 molecular analysis Methods 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000004458 analytical method Methods 0.000 claims description 39
- -1 poly(ethylene glycol) Polymers 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000000834 fixative Substances 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 230000002380 cytological effect Effects 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003431 cross linking reagent Substances 0.000 claims description 13
- 238000006731 degradation reaction Methods 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 10
- 239000002738 chelating agent Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 claims description 7
- 238000004445 quantitative analysis Methods 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 230000003139 buffering effect Effects 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 3
- HLVXFWDLRHCZEI-UHFFFAOYSA-N chromotropic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HLVXFWDLRHCZEI-UHFFFAOYSA-N 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- LJYRLGOJYKPILZ-UHFFFAOYSA-N murexide Chemical compound [NH4+].N1C(=O)NC(=O)C(N=C2C(NC(=O)NC2=O)=O)=C1[O-] LJYRLGOJYKPILZ-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- XSXPMEFGYQQBHC-UHFFFAOYSA-N 4-hydroxy-3-nitronaphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C(S(O)(=O)=O)C2=C1 XSXPMEFGYQQBHC-UHFFFAOYSA-N 0.000 claims 1
- 229940122426 Nuclease inhibitor Drugs 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 238000012511 carbohydrate analysis Methods 0.000 claims 1
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 183
- 239000000523 sample Substances 0.000 description 46
- 238000003556 assay Methods 0.000 description 45
- 239000000203 mixture Substances 0.000 description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- 239000002609 medium Substances 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 26
- 238000003860 storage Methods 0.000 description 17
- 238000010186 staining Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 12
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 11
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- KMQKYDWPAZMUDX-UHFFFAOYSA-M sodium;hydrogen sulfite;pentanedial Chemical compound [Na+].OS([O-])=O.O=CCCCC=O KMQKYDWPAZMUDX-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 8
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010008263 Cervical dysplasia Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000012742 biochemical analysis Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000002895 hyperchromatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005088 multinucleated cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- YVGZCLMIVQGEPB-UHFFFAOYSA-N 1,5-dihydroxypentane-1,5-disulfonic acid Chemical group OS(=O)(=O)C(O)CCCC(O)S(O)(=O)=O YVGZCLMIVQGEPB-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091007743 BRCA1/2 Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010068322 Oral papilloma Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical class [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pens And Brushes (AREA)
- Developing Agents For Electrophotography (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007203372A AU2007203372B2 (en) | 2000-06-21 | 2007-07-19 | Universal collection medium |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59857100A | 2000-06-21 | 2000-06-21 | |
| US09/598,571 | 2000-06-21 | ||
| PCT/US2001/041091 WO2001098542A2 (en) | 2000-06-21 | 2001-06-21 | Universal collection medium |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007203372A Division AU2007203372B2 (en) | 2000-06-21 | 2007-07-19 | Universal collection medium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2002215488A1 AU2002215488A1 (en) | 2002-03-21 |
| AU2002215488B2 AU2002215488B2 (en) | 2007-04-19 |
| AU2002215488B8 true AU2002215488B8 (en) | 2007-11-15 |
Family
ID=24396098
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002215488A Ceased AU2002215488B8 (en) | 2000-06-21 | 2001-06-21 | Universal collection medium |
| AU1548802A Pending AU1548802A (en) | 2000-06-21 | 2001-06-21 | Universal collection medium |
| AU2007203372A Ceased AU2007203372B2 (en) | 2000-06-21 | 2007-07-19 | Universal collection medium |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU1548802A Pending AU1548802A (en) | 2000-06-21 | 2001-06-21 | Universal collection medium |
| AU2007203372A Ceased AU2007203372B2 (en) | 2000-06-21 | 2007-07-19 | Universal collection medium |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7371518B2 (https=) |
| EP (1) | EP1294853B1 (https=) |
| JP (1) | JP2012034699A (https=) |
| AT (1) | ATE466930T1 (https=) |
| AU (3) | AU2002215488B8 (https=) |
| BR (1) | BR0112385A (https=) |
| CA (1) | CA2414102A1 (https=) |
| DE (1) | DE60142048D1 (https=) |
| WO (1) | WO2001098542A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999031273A2 (en) * | 1997-12-12 | 1999-06-24 | Digene Corporation | Universal collection medium |
| US20040115692A1 (en) * | 2000-04-03 | 2004-06-17 | Cytyc Corporation | Methods, compositions and apparatuses for detecting a target in a preservative solution |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| EP1413874A1 (en) | 2002-10-16 | 2004-04-28 | Streck Laboratories, Inc. | Method and device for collecting and preserving cells for analysis |
| EP1605244A1 (en) * | 2004-06-09 | 2005-12-14 | Boon, Mathilde Elisabeth | Fixative composition |
| JP5566111B2 (ja) | 2007-11-20 | 2014-08-06 | オリンパス株式会社 | Ｒｎａ回収方法 |
| JP2011518333A (ja) * | 2008-04-17 | 2011-06-23 | キアジェン ゲイサーズバーグ インコーポレイテッド | 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット |
| EP2287331A4 (en) | 2008-05-12 | 2012-01-25 | Olympus Corp | PROCESS FOR PROCESSING EXCREMENTS AND CONTAINERS FOR PROCESSING EXCREMENTS |
| WO2010062546A1 (en) | 2008-10-27 | 2010-06-03 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay on an automated platform |
| ES2556771T3 (es) * | 2009-01-19 | 2016-01-20 | bioMérieux S.A. | Procedimientos para determinar la susceptibilidad de contraer una infección nosocomial en un paciente y para establecer un pronóstico de evolución de un síndrome séptico |
| US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| DE202010018569U1 (de) | 2009-02-18 | 2017-09-26 | Streck Inc. | Konservierung zellfreier Nukleinsäuren |
| EP2425019B1 (en) | 2009-05-01 | 2014-03-19 | QIAGEN Gaithersburg, Inc. | A non-target amplification method for detection of rna splice-forms in a sample |
| JP5826752B2 (ja) | 2009-09-14 | 2015-12-02 | キアジェン ゲイサーズバーグ インコーポレイテッド | 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法 |
| CA2787781A1 (en) | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Method of determining and confirming the presence of an hpv in a sample |
| CA2787924A1 (en) * | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| WO2011146683A1 (en) * | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| JP2013528049A (ja) | 2010-05-19 | 2013-07-08 | キアゲン ガイサーズバーグ アイエヌシー． | 核酸の配列特異的な精製及び多重分析のための方法及び組成物 |
| US20130095473A1 (en) | 2010-06-14 | 2013-04-18 | Qiagen Gmbh | Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples |
| EP2638396B1 (en) | 2010-11-12 | 2017-03-01 | incellDX, Inc. | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (cin) lesion from a suspension sample of cervical cells |
| CN103597095B (zh) | 2011-02-24 | 2016-08-17 | 奇亚根盖瑟斯堡股份有限公司 | 用于检测hpv核酸的材料和方法 |
| US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| ES2938048T3 (es) | 2013-07-24 | 2023-04-04 | Streck Llc | Composiciones y procedimientos para estabilizar las células tumorales circulantes |
| JP6664332B2 (ja) * | 2014-03-18 | 2020-03-13 | キアゲン ゲーエムベーハー | 細胞外核酸の安定化および単離 |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| US10365189B2 (en) * | 2015-05-07 | 2019-07-30 | Steven Wheeler | Histological specimen treatment |
| US12366508B2 (en) | 2015-07-30 | 2025-07-22 | Qiagen Gmbh | Method of preparing a frozen biological sample |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| EP4656715A3 (en) | 2016-07-29 | 2026-02-25 | Streck LLC | Suspension composition for hematology analysis control |
| CN106929421B (zh) * | 2017-02-27 | 2020-12-01 | 中国计量科学研究院 | 定量保存微生物的冷冻干燥小球的制备方法 |
| CN115119829B (zh) | 2017-10-19 | 2024-07-12 | 斯特雷克股份有限公司 | 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US129223A (en) * | 1872-07-16 | Improvement in privy-seats | ||
| US133972A (en) * | 1872-12-17 | Improvement in bolt-trimmers | ||
| US4578282A (en) * | 1982-02-04 | 1986-03-25 | Harrison James S | Composition for diagnostic reagents |
| US4493821A (en) * | 1982-02-04 | 1985-01-15 | Harrison James S | Preservative and fixative preparations for biological systems |
| US4465078A (en) | 1982-09-30 | 1984-08-14 | Medtest Corporation | Method for cell sampling in a body cavity |
| DE3319564A1 (de) * | 1983-05-30 | 1984-12-06 | Arthur Pfeiffer Vakuumtechnik Wetzlar Gmbh, 6334 Asslar | Verfahren zur herstellung flexibler, dauerhaltbargemachter nicht konservierter und konservierter biologischer materialien |
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US5580970A (en) | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
| JPH05501650A (ja) | 1989-12-01 | 1993-04-02 | バイシス・インコーポレーテツド | Ｈｐｖ転写物の検出 |
| US5256571A (en) | 1991-05-01 | 1993-10-26 | Cytyc Corporation | Cell preservative solution |
| US5543294A (en) | 1991-07-19 | 1996-08-06 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria |
| IL106273A0 (en) | 1992-07-17 | 1993-11-15 | Res Dev Foundation | Rapid detection of biopolymers in stained specimens |
| US5357977A (en) * | 1993-04-23 | 1994-10-25 | St. Mary's Hospital And Medical Center, Inc. | Cytological sampling method and device |
| US5370128A (en) | 1993-12-02 | 1994-12-06 | Wainwright; Sharon R. | Pap brush and pap unit container systems |
| CA2147593C (en) * | 1994-04-22 | 2008-07-29 | Hyman C. Birnboim | Dual purpose tissue fixative |
| US5679333A (en) * | 1996-10-25 | 1997-10-21 | Dunphy; Brian William | Formaldehyde-free tissue preservative compositions |
| GB9709728D0 (en) * | 1997-05-13 | 1997-07-02 | Dynal As | Single step method |
| WO1999031273A2 (en) | 1997-12-12 | 1999-06-24 | Digene Corporation | Universal collection medium |
-
2001
- 2001-06-21 AU AU2002215488A patent/AU2002215488B8/en not_active Ceased
- 2001-06-21 EP EP01984035A patent/EP1294853B1/en not_active Expired - Lifetime
- 2001-06-21 CA CA002414102A patent/CA2414102A1/en not_active Abandoned
- 2001-06-21 DE DE60142048T patent/DE60142048D1/de not_active Expired - Lifetime
- 2001-06-21 AU AU1548802A patent/AU1548802A/xx active Pending
- 2001-06-21 BR BR0112385-8A patent/BR0112385A/pt not_active IP Right Cessation
- 2001-06-21 AT AT01984035T patent/ATE466930T1/de not_active IP Right Cessation
- 2001-06-21 WO PCT/US2001/041091 patent/WO2001098542A2/en not_active Ceased
-
2003
- 2003-01-24 US US10/351,149 patent/US7371518B2/en not_active Expired - Fee Related
-
2007
- 2007-07-19 AU AU2007203372A patent/AU2007203372B2/en not_active Ceased
-
2011
- 2011-09-30 JP JP2011216080A patent/JP2012034699A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004500897A (ja) | 2004-01-15 |
| EP1294853B1 (en) | 2010-05-05 |
| BR0112385A (pt) | 2003-06-17 |
| AU2007203372B2 (en) | 2011-02-03 |
| AU2002215488B2 (en) | 2007-04-19 |
| WO2001098542A3 (en) | 2002-06-20 |
| JP2012034699A (ja) | 2012-02-23 |
| CA2414102A1 (en) | 2001-12-27 |
| US20030119049A1 (en) | 2003-06-26 |
| ATE466930T1 (de) | 2010-05-15 |
| EP1294853A2 (en) | 2003-03-26 |
| AU2007203372A1 (en) | 2007-08-09 |
| JP4879447B2 (ja) | 2012-02-22 |
| WO2001098542A2 (en) | 2001-12-27 |
| AU1548802A (en) | 2002-01-02 |
| DE60142048D1 (de) | 2010-06-17 |
| US7371518B2 (en) | 2008-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007203372B2 (en) | Universal collection medium | |
| AU748022B2 (en) | Universal collection medium | |
| AU2002215488A1 (en) | Universal collection medium | |
| Ambros et al. | Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines | |
| EP3225685B1 (en) | Cell preservative solution, use of same, and method for producing cell preservative solution | |
| US6337189B1 (en) | Fixative system, method and composition for biological testing | |
| CN100408696C (zh) | 保存溶液中目标的检测 | |
| Tisserand et al. | ThinPrep®‐processed fine‐needle samples of breast are effective material for RNA‐and DNA‐based molecular diagnosis: Application to p53 mutation analysis | |
| KR20050043882A (ko) | 고형 담체에 투여되어 저장되고 그리고 탐지되는 핵산 | |
| JP4879447B6 (ja) | 汎用収集用保存液 | |
| Ben-Ezra et al. | Can polymerase chain reaction help distinguish benign from malignant lymphoid aggregates in bone marrow aspirates? | |
| JP2004500897A5 (https=) | ||
| Bagasra et al. | In Situ PCR: Current Protocol | |
| Mazellier et al. | Papillomavirus genotyping on formaldehyde fixed paraffin-embedded tissues in vulvar intraepithelial neoplasia | |
| CN115287336A (zh) | 一种检测人淋巴细胞eb病毒感染和免疫检查点表达水平的方法 | |
| Zabka et al. | Diagnostic techniques in aquatic animal medicine | |
| Hanson | The Development of a" Genetic Eyewitness" Profiling System For Low Template Forensic Specimens: Identification of Novel Protein, RNA, and DNA Biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 21, NO 15, PAGE(S) 1799 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME DIGENE CORPORATION, APPLICATION NUMBER 2002215488, CORRECT THE INVENTORS NAME TO READ LORINCZ, ATTILA T. AND TANG, YANLIN |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |